Putnam Investments’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $25.2M | Buy |
97,475
+477
| +0.5% | +$117K | 0.03% | 198 |
|
|
2023
Q3 | $24.9M | Sell |
96,998
-318
| -0.3% | -$85.1K | 0.04% | 180 |
|
|
2023
Q2 | $27.7M | Buy |
97,316
+11,105
| +13% | +$3.31M | 0.04% | 177 |
|
|
2023
Q1 | $24M | Sell |
86,211
-60,843
| -41% | -$16.8M | 0.04% | 190 |
|
|
2022
Q4 | $40.7M | Buy |
147,054
+98,843
| +205% | +$27.9M | 0.07% | 155 |
|
|
2022
Q3 | $12.9M | Buy |
+48,211
| New | +$10.2M | 0.02% | 247 |
|
|
2022
Q1 | – | Sell |
-133,350
| Closed | -$32M | – | 1185 |
|
|
2021
Q4 | $32M | Sell |
133,350
-18,311
| -12% | -$4.71M | 0.05% | 194 |
|
|
2021
Q3 | $42.9M | Sell |
151,661
-1,081
| -0.7% | -$354K | 0.07% | 184 |
|
|
2021
Q2 | $52.9M | Sell |
152,742
-74,536
| -33% | -$22.6M | 0.08% | 164 |
|
|
2021
Q1 | $63.6M | Buy |
227,278
+102,793
| +83% | +$27.7M | 0.11% | 161 |
|
|
2020
Q4 | $30.5M | Sell |
124,485
-77,184
| -38% | -$19.9M | 0.05% | 205 |
|
|
2020
Q3 | $57.2M | Buy |
201,669
+26,504
| +15% | +$7.39M | 0.11% | 151 |
|
|
2020
Q2 | $46.9M | Sell |
175,165
-131,642
| -43% | -$39.6M | 0.1% | 151 |
|
|
2020
Q1 | $97.1M | Buy |
306,807
+68,737
| +29% | +$20.9M | 0.25% | 103 |
|
|
2019
Q4 | $70.6M | Sell |
238,070
-3,887
| -2% | -$1.08M | 0.15% | 145 |
|
|
2019
Q3 | $56.3M | Buy |
241,957
+30,209
| +14% | +$7.03M | 0.13% | 155 |
|
|
2019
Q2 | $49.5M | Buy |
211,748
+1,661
| +0.8% | +$384K | 0.11% | 172 |
|
|
2019
Q1 | $49.7M | Sell |
210,087
-395,306
| -65% | -$124M | 0.12% | 166 |
|
|
2018
Q4 | $182M | Buy |
605,393
+108,895
| +22% | +$34.8M | 0.48% | 61 |
|
|
2018
Q3 | $175M | Buy |
496,498
+365,621
| +279% | +$126M | 0.38% | 73 |
|
|
2018
Q2 | $38M | Sell |
130,877
-190,583
| -59% | -$53.6M | 0.09% | 194 |
|
|
2018
Q1 | $88M | Sell |
321,460
-477,912
| -60% | -$148M | 0.2% | 124 |
|
|
2017
Q4 | $255M | Buy |
799,372
+142,949
| +22% | +$45.9M | 0.57% | 40 |
|
|
2017
Q3 | $206M | Sell |
656,423
-153,878
| -19% | -$45.6M | 0.47% | 54 |
|
|
2017
Q2 | $220M | Buy |
810,301
+23,332
| +3% | +$6.17M | 0.51% | 44 |
|
|
2017
Q1 | $215M | Sell |
786,969
-23,576
| -3% | -$6.67M | 0.51% | 45 |
|
|
2016
Q4 | $230M | Buy |
810,545
+85,492
| +12% | +$25.3M | 0.55% | 43 |
|
|
2016
Q3 | $227M | Buy |
725,053
+56,892
| +9% | +$16.9M | 0.55% | 45 |
|
|
2016
Q2 | $162M | Buy |
668,161
+64,552
| +11% | +$17M | 0.39% | 60 |
|
|
2016
Q1 | $157M | Buy |
603,609
+82,098
| +16% | +$21.7M | 0.37% | 62 |
|
|
2015
Q4 | $160M | Sell |
521,511
-70,984
| -12% | -$20.4M | 0.36% | 60 |
|
|
2015
Q3 | $173M | Sell |
592,495
-110,781
| -16% | -$36.6M | 0.39% | 53 |
|
|
2015
Q2 | $284M | Buy |
703,276
+83,031
| +13% | +$33.3M | 0.57% | 35 |
|
|
2015
Q1 | $262M | Buy |
620,245
+85,101
| +16% | +$33.5M | 0.52% | 38 |
|
|
2014
Q4 | $182M | Buy |
535,144
+80,484
| +18% | +$26M | 0.37% | 60 |
|
|
2014
Q3 | $150M | Buy |
454,660
+12,764
| +3% | +$4.21M | 0.32% | 72 |
|
|
2014
Q2 | $139M | Buy |
441,896
+233,748
| +112% | +$70.4M | 0.3% | 80 |
|
|
2014
Q1 | $63.7M | Buy |
208,148
+181,608
| +684% | +$57.6M | 0.14% | 156 |
|
|
2013
Q4 | $7.42M | Buy |
26,540
+17,336
| +188% | +$4.48M | 0.02% | 579 |
|
|
2013
Q3 | $2.22M | Sell |
9,204
-75,124
| -89% | -$16.8M | 0.01% | 1031 |
|
|
2013
Q2 | $18.1M | Buy |
+84,328
| New | +$18M | 0.05% | 319 |
|
Other funds holding BIIB
Putnam Investments's BIIB Position: Q4 2023 in Review
Putnam Investments increased its Biogen (BIIB) stake by 0.49% in Q4 2023, buying an estimated $117K and bringing the position to 97,475 shares worth $25.2M. The position accounts for 0.03% of the portfolio, ranked #198.
Putnam Investments first reported a position in BIIB in Q2 2013 and has held it in 41 quarters since. The position peaked at $284M in Q2 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q4 2023.
- Putnam Investments held 97,475 shares of Biogen worth $25.2M as of Q4 2023.
- Putnam Investments bought 477 Biogen shares in Q4 2023, an estimated $117K.
- Biogen made up 0.03% of Putnam Investments's portfolio in Q4 2023, its #198 holding.
- Putnam Investments first reported a position in Biogen in Q2 2013 and has held it in 41 quarters since.
- Putnam Investments's Biogen position peaked at $284M in Q2 2015.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q4 2023.
Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.